Due to the high number of Xarelto lawsuits that have been filed in the last few months, over 2,200 Xarelto litigations have been consolidated in a large Multi-District panel overseen by Judge Eldon Fallon in the Eastern District of Louisiana. The bellwether trial for Xarelto MDL number 2592 will be held on January 11th, 2016. Plaintiffs who asked for a Xarelto attorney to bring their cases to court are claiming Bayer AG and Janssen Pharmaceuticals’ (a division of Johnson & Johnson) responsible for the injuries they sustained.
Xarelto is a famous anticoagulant medication which is routinely prescribed to treat and prevent pulmonary embolism and deep venous thrombosis, and to reduce the risk of stroke in patients who suffer from atrial fibrillation. However, the drug has been deemed very dangerous by several health organizations, as it’s associated with several uncontrolled bleeding events. To make things worse, no Xarelto antidote is available to reverse its effects, and for this reason, many people died or suffered serious harm by using this anticoagulant medication. Whenever a patient starts bleeding because of Xarelto side effects, doctors have no way to stop the hemorrhage other than just waiting. On the other hand, the action of older anticoagulants like Warfarin could be reversed by promptly administering Vitamin K in emergency rooms.
Xarelto attorneys are asking for compensation for all people who suffered an injury caused by Xarelto side effects, or for the relatives of those who died because of Xarelto adverse reactions. Since the MDL has consolidated over 2,200 cases, the number of Xarelto lawsuits filed never stopped growing. It is expected that many more will keep being filed through the new year, although just a few have been selected as the most representative cases. Xarelto’s manufacturers Bayer AG and Janssen Pharmaceuticals have been accused of negligence in warning people about Xarelto dangers, and of releasing a drug to the market without thoroughly checking its safety. Plaintiffs also accuse the pharmaceutical companies of fraudulently marketing the drug as “safer” than its counterpart Warfarin.
Article written by: Dr. Claudio Butticè, Pharm.D.